Additional analyses from a sub study in the SYNCHRONIZE-1 trial in people living with obesity without T2D (n=75) were presented... (Boehringer Ingelheim Press Release) - Oct 1, 2026 - "MRI-based body composition assessments further reinforced the fat-targeting profile of survodutide, demonstrating preferential reductions in metabolically active visceral and liver fat. The overall pattern of body composition change suggests a favorable shift away from excessive accumulation of fat around the abdomen. Building on previously reported lean mass findings, a new muscle-specific analysis showed that muscle accounted for no more than 10% of total tissue lost. Importantly, reductions in visceral and liver fat appear largely independent of the degree of weight reduction achieved, suggesting that these benefits may extend beyond weight reduction alone."
P3 data • Obesity
|